TY - JOUR
T1 - Unraveling Parkinson's Disease Neurodegeneration
T2 - Does Aging Hold the Clues?
AU - Coleman, Colin
AU - Martin, Ian
N1 - Funding Information:
The authors thank funding support for this work from The Parkinson’s Foundation, National Institutes of Health (R01NS119226 and R21AG075320 to I.M., T32AG055378 to C.C.) and The OHSU Foundation (I.M.).
Publisher Copyright:
© 2022 - The authors. Published by IOS Press.
PY - 2022
Y1 - 2022
N2 - Aging is the greatest risk factor for Parkinson's disease (PD), suggesting that mechanisms driving the aging process promote PD neurodegeneration. Several lines of evidence support a role for aging in PD. First, hallmarks of brain aging such as mitochondrial dysfunction and oxidative stress, loss of protein homeostasis, and neuroinflammation are centrally implicated in PD development. Second, mutations that cause monogenic PD are present from conception, yet typically only cause disease following a period of aging. Third, lifespan-extending genetic, dietary, or pharmacological interventions frequently attenuate PD-related neurodegeneration. These observations support a central role for aging in disease development and suggest that new discoveries in the biology of aging could be leveraged to elucidate novel mechanisms of PD pathophysiology. A recent rapid growth in our understanding of conserved molecular pathways that govern model organism lifespan and healthspan has highlighted a key role for metabolism and nutrient sensing pathways. Uncovering how metabolic pathways involving NAD+ consumption, insulin, and mTOR signaling link to the development of PD is underway and implicates metabolism in disease etiology. Here, we assess areas of convergence between nervous system aging and PD, evaluate the link between metabolism, aging, and PD and address the potential of metabolic interventions to slow or halt the onset of PD-related neurodegeneration drawing on evidence from cellular and animal models.
AB - Aging is the greatest risk factor for Parkinson's disease (PD), suggesting that mechanisms driving the aging process promote PD neurodegeneration. Several lines of evidence support a role for aging in PD. First, hallmarks of brain aging such as mitochondrial dysfunction and oxidative stress, loss of protein homeostasis, and neuroinflammation are centrally implicated in PD development. Second, mutations that cause monogenic PD are present from conception, yet typically only cause disease following a period of aging. Third, lifespan-extending genetic, dietary, or pharmacological interventions frequently attenuate PD-related neurodegeneration. These observations support a central role for aging in disease development and suggest that new discoveries in the biology of aging could be leveraged to elucidate novel mechanisms of PD pathophysiology. A recent rapid growth in our understanding of conserved molecular pathways that govern model organism lifespan and healthspan has highlighted a key role for metabolism and nutrient sensing pathways. Uncovering how metabolic pathways involving NAD+ consumption, insulin, and mTOR signaling link to the development of PD is underway and implicates metabolism in disease etiology. Here, we assess areas of convergence between nervous system aging and PD, evaluate the link between metabolism, aging, and PD and address the potential of metabolic interventions to slow or halt the onset of PD-related neurodegeneration drawing on evidence from cellular and animal models.
KW - Aging
KW - Parkinson's disease
KW - metabolism
KW - mitochondria
UR - http://www.scopus.com/inward/record.url?scp=85144637096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144637096&partnerID=8YFLogxK
U2 - 10.3233/JPD-223363
DO - 10.3233/JPD-223363
M3 - Review article
C2 - 36278358
AN - SCOPUS:85144637096
SN - 1877-7171
VL - 12
SP - 2321
EP - 2338
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
IS - 8
ER -